Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: INGR stock price vs PTCT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PTCT's multiple
Needs PTCT P/E.
Implied fair value · at INGR's multiple
Needs INGR P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INGR FY 2025 (ended Dec 31, 2025) · PTCT FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 78% equity / 22% debt · EV / Revenue 0.99x · EV / EBITDA 5.82x
Capital structure 95% equity / 5% debt · EV / Revenue 2.38x · EV / EBITDA 5.50x
INGR carries the larger enterprise value at $7.14B against $4.13B; INGR trades on the lower EV / Revenue multiple (0.99x vs 2.38x); PTCT on the lower EV / EBITDA (5.50x vs 5.82x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
INGREDION INCORPORATED · implied price per share
Bear
$72.68
Base
$85.13
Bull
$104.12
PTC Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.42x
-1.40x
Net debt / EBITDA
Leverage against operating earnings
0.62x
-2.21x
Cash and equivalents
Liquid reserves on the balance sheet
$1.04B
$1.95B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Archer-Daniels-Midland Co
INGR vs ADM
HERSHEY CO
INGR vs HSY
KELLANOVA
INGR vs K
INTERNATIONAL FLAVORS & FRAGRANCES INC
INGR vs IFF
VERTEX PHARMACEUTICALS INC / MA
INGR vs VRTX
Sarepta Therapeutics, Inc.
INGR vs SRPT
BIOMARIN PHARMACEUTICAL INC
INGR vs BMRN
ALNYLAM PHARMACEUTICALS, INC.
INGR vs ALNY
$1.79B
$286.63M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
